Logo

BioXcel Initiates P-III (TRANQUILITY) Program of BXCL501 for the Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Share this

BioXcel Initiates P-III (TRANQUILITY) Program of BXCL501 for the Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Shots:

  • The company initiates P-III (TRANQUILITY II/III) studies to evaluate BXCL501 (40/60mcg) in 300 patients aged ≥65yrs. with AD in assisted living, residential facilities, and nursing homes. Following the completion of TRANQUILITY II/III studies, patients will enroll in an open-label, 52wks. safety study
  • The studies are designed to evaluate agitation as measured by changes from baseline in the PEC & PAS total scores. The 1EPs for both studies will be a change in PEC score from baseline measured @2hrs. after the initial & subsequent doses
  • The therapy received BTD for agitation associated with dementia & FTD for agitation associated with schizophrenia, bipolar disorders & dementia

Ref: Globe Newswire | Image: Bioexcel

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions